基于血液的生物标志物筛查癌前结直肠病变的准确性：系统评价和荟萃分析方案。
Accuracy of blood-based biomarkers for screening precancerous colorectal lesions: a protocol for systematic review and meta-analysis.
机构信息
Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Flinders Centre for Innovation in Cancer, Bedford Park, South Australia, Australia
Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Flinders Centre for Innovation in Cancer, Bedford Park, South Australia, Australia.
出版信息
BMJ Open. 2022 May 30;12(5):e060712. doi: 10.1136/bmjopen-2021-060712.
INTRODUCTION
Colorectal cancer (CRC) is the third most diagnosed cancer and the second most common cause of cancer mortality worldwide. Most CRCs develop through either the adenoma-to-carcinoma or the serrated pathways, and, therefore, detection and removal of these precursor lesions can prevent the development of cancer. Current screening programmes can aid in the detection of CRC and adenomas; however, participation rates are suboptimal. Blood-based biomarkers may help to address these low participation rates in screening programmes. Although blood-based biomarker tests show promise for cancer detection, limited attention has been placed on the sensitivity and specificity for detection of the precursor lesions. The aim of this research is to conduct a systematic review and meta-analysis to evaluate the accuracy of blood-based biomarker tests in detecting advanced precancerous lesions.
METHODS AND ANALYSIS
This protocol was informed by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses-Protocols (PRISMA-P) and results will be reported in line with the PRISMA guidelines. Literature searches will be conducted on PubMed, Embase and Web of Science. Two reviewers will conduct the searches, and independently screen them, according to title and abstract and then the full-text versions of those selected articles as well as the risk of bias via the Quality Assessment of Diagnostic Accuracy Studies version 2 (QUADAS-2) tool. The Grading of Recommendations Assessment, Development and Evaluation guidelines will be used to validate the certainty of evidence for recommendations based on the risk of bias findings. Meta-analysis will be conducted where appropriate on groups of studies with low heterogeneity.
ETHICS AND DISSEMINATION
No patient data will be included in our review and, therefore, ethics approval is not required. It is anticipated that the review will identify the most promising candidate biomarkers for clinical translation in the screening of advanced precancerous lesions. The results will be published in a peer-reviewed journal.
PROSPERO REGISTRATION NUMBER
CRD42021285173.
简介
结直肠癌（CRC）是全球第三大被诊断出的癌症，也是第二大常见的癌症死亡原因。大多数 CRC 是通过腺瘤-癌或锯齿状途径发展而来的，因此，检测和去除这些前体病变可以预防癌症的发生。目前的筛查计划可以帮助检测 CRC 和腺瘤；然而，参与率并不理想。基于血液的生物标志物可能有助于解决这些筛查计划中的低参与率问题。尽管基于血液的生物标志物检测在癌症检测方面显示出了一定的前景，但对于检测前体病变的敏感性和特异性关注有限。本研究旨在进行系统评价和荟萃分析，以评估基于血液的生物标志物检测在检测高级癌前病变中的准确性。
方法和分析
本方案遵循系统评价和荟萃分析的首选报告项目-议定书（PRISMA-P），并将按照 PRISMA 指南报告结果。文献检索将在 PubMed、Embase 和 Web of Science 上进行。两名评审员将根据标题和摘要进行搜索，并独立筛选，然后筛选出选定文章的全文版本以及通过质量评估诊断准确性研究版本 2（QUADAS-2）工具评估的偏倚风险。将使用推荐评估、制定和评估指南来验证基于偏倚发现的推荐的证据确定性。在适当的情况下，将对具有低异质性的研究组进行荟萃分析。
伦理和传播
我们的综述不包括患者数据，因此不需要伦理批准。预计该综述将确定最有前途的候选生物标志物，用于在高级癌前病变的筛查中进行临床转化。研究结果将发表在同行评议的期刊上。
前瞻性注册号码
CRD42021285173。
Zotero 插件